CStone Pharmaceuticals PH4.F Stock
CStone Pharmaceuticals Price Chart
CStone Pharmaceuticals PH4.F Financial and Trading Overview
| CStone Pharmaceuticals stock price | 0.17 EUR |
| Previous Close | 0.3 EUR |
| Open | 0.32 EUR |
| Bid | 0.31 EUR x 182700 |
| Ask | 0.34 EUR x 172600 |
| Day's Range | 0.32 - 0.32 EUR |
| 52 Week Range | 0.28 - 0.71 EUR |
| Volume | 200 EUR |
| Avg. Volume | 76 EUR |
| Market Cap | 431.66M EUR |
| Beta (5Y Monthly) | 0.151099 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.04 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PH4.F Valuation Measures
| Enterprise Value | -506435008 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.8967408 |
| Price/Book (mrq) | 0.8608 |
| Enterprise Value/Revenue | -1.052 |
| Enterprise Value/EBITDA | 0.566 |
Trading Information
CStone Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.151099 |
| 52-Week Change | -51.72% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.71 EUR |
| 52 Week Low | 0.28 EUR |
| 50-Day Moving Average | 0.37 EUR |
| 200-Day Moving Average | 0.46 EUR |
PH4.F Share Statistics
| Avg. Volume (3 month) | 76 EUR |
| Avg. Daily Volume (10-Days) | 20 EUR |
| Shares Outstanding | 1.28B |
| Float | 561.86M |
| Short Ratio | N/A |
| % Held by Insiders | 44.68% |
| % Held by Institutions | 15.61% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -187.52% |
| Operating Margin (ttm) | -189.49% |
| Gross Margin | 57.83% |
| EBITDA Margin | -186.014% |
Management Effectiveness
| Return on Assets (ttm) | -29.16% |
| Return on Equity (ttm) | -108.99% |
Income Statement
| Revenue (ttm) | 481.36M EUR |
| Revenue Per Share (ttm) | 0.41 EUR |
| Quarterly Revenue Growth (yoy) | 33.70% |
| Gross Profit (ttm) | N/A |
| EBITDA | -895406976 EUR |
| Net Income Avi to Common (ttm) | -902678016 EUR |
| Diluted EPS (ttm) | -0.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.15B EUR |
| Total Cash Per Share (mrq) | 0.96 EUR |
| Total Debt (mrq) | 286.29M EUR |
| Total Debt/Equity (mrq) | 63.72 EUR |
| Current Ratio (mrq) | 1.317 |
| Book Value Per Share (mrq) | 0.375 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -612468992 EUR |
| Levered Free Cash Flow (ttm) | -398404992 EUR |
Profile of CStone Pharmaceuticals
| Country | Germany |
| State | N/A |
| City | Suzhou |
| Address | C1 Building |
| ZIP | 215123 |
| Phone | 86 512 8718 6550 |
| Website | https://www.cstonepharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 476 |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.
Q&A For CStone Pharmaceuticals Stock
What is a current PH4.F stock price?
CStone Pharmaceuticals PH4.F stock price today per share is 0.17 EUR.
How to purchase CStone Pharmaceuticals stock?
You can buy PH4.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CStone Pharmaceuticals?
The stock symbol or ticker of CStone Pharmaceuticals is PH4.F.
Which industry does the CStone Pharmaceuticals company belong to?
The CStone Pharmaceuticals industry is Biotechnology.
How many shares does CStone Pharmaceuticals have in circulation?
The max supply of CStone Pharmaceuticals shares is 1.29B.
What is CStone Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
CStone Pharmaceuticals PE Ratio is now.
What was CStone Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
CStone Pharmaceuticals EPS is -0.04 EUR over the trailing 12 months.
Which sector does the CStone Pharmaceuticals company belong to?
The CStone Pharmaceuticals sector is Healthcare.